Company profile for Brenus Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance.Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment. Brenus has developed STC (Stimulated Tumor Cells), a technology platform mimicking relapsing conditions and enabling the education of patients' immune system, to fight against the re...
Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance.Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment. Brenus has developed STC (Stimulated Tumor Cells), a technology platform mimicking relapsing conditions and enabling the education of patients' immune system, to fight against the resistance mechanisms of tumor cells.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
Issoire, Auvergne
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

BPI Europe

BPI Europe

Not Confirmed

envelop Contact Supplier

BPI Europe

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2026-02-19/brenus-pharma-presented-new-preclinical-and-early-clinical-data-in-colorectal-cancer-during-aacr-imm

PHARMIWEB
19 Feb 2026

https://www.businesswire.com/news/home/20260106391108/en/Brenus-Pharma-Reports-Favorable-Tolerability-and-Clinical-Signals-in-Early-Preliminary-Results-of-First-In-Human-Study-for-STC-1010-in-Unresectable-Metastatic-Stage-Colorectal-Cancer-MSS-CRC-Patients

BUSINESSWIRE
06 Jan 2026

https://www.businesswire.com/news/home/20251112049028/en/Brenus-Pharma-Expands-Its-Global-Scientific-Advisory-Board-With-Us-Immuno-Oncology-Expert-Prof.-Olivera-J.-Finn

BUSINESSWIRE
12 Nov 2025

https://www.businesswire.com/news/home/20250901588403/en/Brenus-Pharma-Announces-First-Patients-Dosed-in-its-First-in-Human-Trial-Evaluating-STC-1010-a-Next-Generation-Immunotherapy

BUSINESSWIRE
02 Sep 2025

https://www.businesswire.com/news/home/20250618487695/en/Brenus-Pharma-and-InSphero-Have-Developed-3D-Tumor-Spheroids-Mimicking-in-vivo-Human-Colorectal-Cancer-Conditions-and-Confirming-STC-1010s-Efficacy

BUSINESSWIRE
19 Jun 2025

https://www.businesswire.com/news/home/20250507231535/en/AACR-2025-Brenus-Pharma-Presents-Late-breaking-Preclinical-Data-on-its-off-the-shelf-Next-generation-Vaccine-based-Immunotherapy-Candidate-STC-1010-Now-Moving-to-Clinic

BUSINESSWIRE
07 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty